Toxicities of CAR T-Cell Therapy and the Role of the Consultation-Liaison Psychiatrist

Chimeric antigen receptor (CAR) T-cell therapy is a promising novel T-cell immunotherapy in cancer treatment that has shown clinical efficacy in treating refractory CD19+ B-cell malignancies. However, its use is associated with severe immune-mediated toxicities, including cytokine release syndrome (CRS) and CAR T-cell-related encephalopathy syndrome (CRES). CRS is a systemic inflammatory immune response resulting in symptoms ranging from constitutional to profound organ dysfunction; CRES is a neurotoxicity that can occur concurrently or separately from CRS.
Source: Psychosomatics - Category: Psychiatry & Psychology Authors: Tags: Manuscript ID: Psycho-18-09-0267.R1 Source Type: research